SG10202011665SA - Fused bicyclic compounds for the treatment of disease - Google Patents

Fused bicyclic compounds for the treatment of disease

Info

Publication number
SG10202011665SA
SG10202011665SA SG10202011665SA SG10202011665SA SG10202011665SA SG 10202011665S A SG10202011665S A SG 10202011665SA SG 10202011665S A SG10202011665S A SG 10202011665SA SG 10202011665S A SG10202011665S A SG 10202011665SA SG 10202011665S A SG10202011665S A SG 10202011665SA
Authority
SG
Singapore
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
SG10202011665SA
Other languages
English (en)
Inventor
Raju Mohan
Benjamin Pratt
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of SG10202011665SA publication Critical patent/SG10202011665SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
SG10202011665SA 2016-05-25 2017-05-25 Fused bicyclic compounds for the treatment of disease SG10202011665SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341483P 2016-05-25 2016-05-25
US201662341486P 2016-05-25 2016-05-25

Publications (1)

Publication Number Publication Date
SG10202011665SA true SG10202011665SA (en) 2020-12-30

Family

ID=60411628

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202011665SA SG10202011665SA (en) 2016-05-25 2017-05-25 Fused bicyclic compounds for the treatment of disease
SG11201810292YA SG11201810292YA (en) 2016-05-25 2017-05-25 Fused bicyclic compounds for the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201810292YA SG11201810292YA (en) 2016-05-25 2017-05-25 Fused bicyclic compounds for the treatment of disease

Country Status (13)

Country Link
US (1) US20200325140A1 (fr)
EP (1) EP3463372A4 (fr)
JP (1) JP2019520335A (fr)
KR (1) KR20190040140A (fr)
CN (1) CN109789149A (fr)
AU (1) AU2017270203A1 (fr)
BR (1) BR112018074231A2 (fr)
CA (1) CA3025326A1 (fr)
IL (1) IL263177A (fr)
MX (1) MX2018014034A (fr)
RU (1) RU2018145721A (fr)
SG (2) SG10202011665SA (fr)
WO (1) WO2017205633A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3221321B1 (fr) * 2014-11-21 2021-12-15 Akarna Therapeutics, Ltd. Composés bicycliques fusionnés pour le traitement d'une maladie
EP4041730A1 (fr) * 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Composés hétéroaryle bicycliques substitués
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532235A (en) * 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
BRPI0412262A (pt) * 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
EP2121621B1 (fr) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Modulateurs lxr et fxr
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
JP2012506848A (ja) * 2008-10-27 2012-03-22 グラクソ グループ リミテッド グルタミン酸受容体モジュレーターとしての三環式化合物
WO2014094357A1 (fr) * 2012-12-21 2014-06-26 Abbvie Inc. Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
JP6843061B2 (ja) * 2015-03-26 2021-03-17 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． 疾患治療のための縮合二環化合物

Also Published As

Publication number Publication date
EP3463372A1 (fr) 2019-04-10
AU2017270203A1 (en) 2019-01-03
CN109789149A (zh) 2019-05-21
RU2018145721A3 (fr) 2020-08-21
KR20190040140A (ko) 2019-04-17
IL263177A (en) 2018-12-31
BR112018074231A2 (pt) 2019-03-06
CA3025326A1 (fr) 2017-11-30
JP2019520335A (ja) 2019-07-18
WO2017205633A1 (fr) 2017-11-30
EP3463372A4 (fr) 2019-11-13
SG11201810292YA (en) 2018-12-28
MX2018014034A (es) 2019-08-29
RU2018145721A (ru) 2020-06-25
US20200325140A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
HK1244802A1 (zh) 用於治療疾病的稠合雙環化合物
HK1245795A1 (zh) 用於治療疾病的稠合雙環化合物
IL253062B (en) Pyrazine compounds for the treatment of infectious diseases
HK1244276A1 (zh) 用於治療hiv的稠合嘧啶化合物
SG10202006688RA (en) Bicyclic compounds for diagnosis and therapy
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
IL265902A (en) Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases
HRP20181672T1 (hr) Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma
HK1249756A1 (zh) 用於治療疾病的稠合雙環化合物
IL259297A (en) Heterocyclic compounds for the treatment of disease
IL263177A (en) Fused bicyclic compounds for the treatment of disease
IL267305A (en) Process for the manufacture of diazepine derivatives
IL270966A (en) Fused bicyclic compounds